Sentiment Summary
Recent Events
Salesforce's Q1 FY2027 earnings release is scheduled.
Lenovo Group is scheduled to release its fourth-quarter and full-year financial results for the fiscal year 2025/2026. Price impact is estimated at ≥10% due to the significance of annual results and guidance, scheduled.
NVIDIA's Q1 Fiscal Year 2027 earnings report is scheduled for May 20, 2026; earnings releases for major tech companies are expected to result in price movements exceeding 10% and are scheduled.
AppLovin's Q1 2026 earnings release is scheduled for May 13, 2026. Based on historical data where earnings results often lead to price swings over 5%, a significant market reaction is expected.
Arista Networks is scheduled to release its Q1 2026 financial results with company revenue of $2.6 billion forecasted; a medium impact is estimated due to typical earnings volatility, scheduled.
Q1 2026 earnings release is scheduled for April 30, 2026, with revenue guidance of approximately $3.1 billion; low impact estimated as it is a routine scheduling announcement scheduled.
The Q1 2026 earnings release, for which high importance is estimated based on historical price volatility and the date is estimated from previous patterns, is scheduled.
Microsoft's fiscal year 2026 third-quarter financial results are scheduled to be released after the market close on April 29, 2026. This major earnings event is estimated to have a price impact of at least 5%, scheduled
Boston Scientific is scheduled to release its Q1 2026 earnings report on April 29, 2026 scheduled.
First quarter 2026 earnings release and conference call scheduled.
Amazon is expected to announce its Q1 2026 financial results after market close on or around this date, scheduled.
Alphabet is expected to announce its Q1 2026 financial results after the market closes on April 23, 2026; low impact is estimated as the date is confirmed but results are pending, scheduled.
Q1 2026 earnings release is scheduled. Analysts forecast earnings of $1.78 per share forecasted.
First quarter 2026 earnings release and webcast; earnings announcements are key volatility drivers for the stock, so this is scheduled.
Q1 2026 earnings release on April 21, 2026, scheduled.
Abbott Laboratories is scheduled to announce its first-quarter 2026 financial results before the market opens on April 16, 2026, scheduled.
Netflix is scheduled to release its Q1 2026 financial results on April 16, 2026, after market close. Analysts forecast an EPS of $0.76. High importance is estimated due to historical volatility around earnings scheduled.
First quarter 2026 earnings release and conference call scheduled.
Booking Holdings Inc. announced a 25-for-1 forward stock split on February 18, 2026. The split was effected after the close on 2026-04-02, and BKNG was scheduled to begin trading on a split-adjusted basis on 2026-04-06.
An online briefing for the 2025 annual report is scheduled for April 1, 2026, where senior management will address investors. This routine event is estimated to have a 1-2% price impact scheduled.
Board meeting to approve the audited annual results for the fiscal year 2025 and consider the payment of a final dividend, scheduled for March 31, 2026. High importance is estimated as annual results and dividend decisions typically impact stock prices by over 10%.
The company is scheduled to release its fiscal year 2025 financial results on March 31, 2026, with analysts forecasting Q4 2025 revenue of CNY 25.76 billion and EPS of CNY 0.420; a price impact of ≥5% is estimated based on historical volatility; scheduled.
Midea Group is scheduled to release its 2025 annual financial results and announce its final dividend on March 31, 2026, expected.
Board meeting to be held on March 30, 2026, to approve and announce the annual results for the year ended December 31, 2025. High importance estimated as annual results typically result in ≥10% price impact, scheduled.
Full year 2025 earnings results and potential final dividend announcement scheduled for March 30, 2026, scheduled. High importance as annual results typically drive significant price movement.
Fiscal Year 2025 earnings release on March 30, 2026, following a board meeting on March 29, 2026, scheduled; analysts forecast a net loss for the year forecasted. High importance is justified by the expected price impact of ≥10% due to continued significant losses.
Board meeting to be held to approve the audited annual results for the year ended December 31, 2025, scheduled.
ZTE Corporation has scheduled its 2025 annual results presentation for March 30, 2026; analysts estimate a price impact of ≥1% and the event is scheduled.
Announced full-year 2025 results on 2026-03-29; analysts forecast revenue up 22.6% and net profit up 27.1%. High importance estimated due to strong growth expected.
Announced full-year 2025 results on 2026-03-28, reporting a net loss of RMB 208.4 million, a significant downturn from the RMB 359.1 million profit in 2024. The loss was attributed to intense competition and increased expenses. This major swing from profit to loss is estimated to cause a >10% price impact, expected.
Announced on 2026-03-28 that accumulated losses exceeded one-third of paid-in capital as of 2025-12-31. The matter will be submitted to a shareholders' meeting for deliberation. This capital erosion signal is estimated to cause a >10% price impact, scheduled.
Boston Scientific announced positive results from two major clinical trials on March 28, 2026; high impact expected due to clinical significance expected.
Amgen announced on March 28, 2026, new Phase 3 trial data for Repatha showing reduced cardiovascular risk; medium impact (>=5%) estimated due to significant clinical data, expected.
Presented positive new long-term 52-week data for ICOTYDE™ at the AAD Annual Meeting on March 28, 2026; moderate impact expected as data supports long-term efficacy and safety.
BYD reported its FY2025 results, marking the first annual profit decline in four years. Net profit fell 19% to 32.6 billion yuan, and revenue grew 3.5%, its slowest pace in six years. This 19% profit decline is estimated to cause a >10% price impact expected.
Announced 2025 annual results on March 27, 2026, with revenue up 10.92% YoY to RMB 3.982 billion, but net profit attributable to shareholders down 59.42% YoY to RMB 232 million. The profit decline was attributed to increased R&D expenses and inventory write-downs. A final dividend of RMB 0.58 per 10 shares was proposed.
Announced FY2025 results on March 27, 2026, with revenue up 16.8% YoY to CNY 14.25 billion and net profit up 20.4% YoY to CNY 814 million. Proposed a final dividend of RMB 0.295 per share.
Announced FY2025 results, reporting revenue of approximately 3.25 billion RMB (89.4% YoY increase) and a net profit of approximately 710 million RMB, achieving a turnaround; High importance reflects the significant financial recovery likely to cause >10% price impact.
The European Medicines Agency's (EMA) CHMP issued a positive opinion on March 27, 2026, recommending marketing authorization for tarlatamab (Imdelltra); high impact (>=10%) estimated due to major regulatory milestone, expected.
Received drug registration approval from China's NMPA on 2026-03-27 for the third indication of Xinyue®; Medium importance estimated as new indications drive growth expected.
The special designation 'U' (unprofitable) was officially removed from the company's A-share stock on March 27, 2026, following its achievement of full-year profitability.
On March 27, 2026, the company repurchased 1.075 million shares for approximately HKD 49.66 million as part of its ongoing buyback program.
The company repurchased 5.35 million of its own shares for a total of HKD 31.44 million on 2026-03-27, which is estimated to have a low price impact (≥1%) as it is a standard buyback.
Proposed a final dividend of RMB 0.358 per share for the fiscal year 2025, payable on August 9, 2026. This proposal is estimated to have a 1-2% price impact expected.
Received European approval on March 27, 2026, for a label update to allow self-administration of DARZALEX® subcutaneous formulation; low impact expected from incremental label expansion.
Shares fell over 13% on March 26, 2026, following the release of 2025 earnings, as investors reacted to plans for a significant increase in 2026 capital expenditure on AI and concerns about slowing future growth.
Announced full-year 2025 financial results on March 26, 2026. Total revenue increased 142% year-over-year to CNY 1.707 billion, and net loss narrowed significantly to CNY 298 million. The company achieved profitability on a non-IFRS basis for the first time. High importance due to significant revenue growth and first-time profitability milestone, expected.
Akeso announced its full-year 2025 financial results on March 26, 2026. Revenue grew 43.9% year-over-year to RMB 3.06 billion, but the net loss widened to RMB 1.11 billion, missing analyst expectations. High importance estimated due to potential for >10% price impact from significant earnings miss, expected.
Announced FY2025 results: Revenue rose 10.3% to RMB 31.83B, and adjusted net profit rose 31.4% to RMB 4.54B. A final dividend of HKD 0.05 per share was proposed, which is estimated to have a medium price impact (≥5%) due to strong profit growth.
Innovent Biologics announced its 2025 annual results, reporting total revenue of RMB 13.04 billion, a 38.4% YoY increase. The company achieved its first full-year net profit of RMB 814 million, a significant turnaround from a net loss in 2024. The stock surged over 7% following the announcement.
Announced full-year 2025 financial results, reporting total revenue of RMB 574.1 million. Sales of core product Olverembatinib grew 81% YoY to RMB 435.3 million, and newly launched Lisaftoclax generated RMB 70.6 million. However, the net loss for the period widened to RMB 1.24 billion. Medium importance estimated due to significant revenue growth in core products; scheduled.
Stock fell approximately 8% on March 26, 2026, amid reports of short-seller allegations regarding market competition and significant insider selling activity.
A class action lawsuit was filed against Boston Scientific on March 26, 2026, alleging misleading statements; medium impact expected due to legal uncertainty expected.
Salesforce announced the deployment of its AI-powered agentic operating system across more than 150 U.S. Veterans Health Administration (VHA) medical centers on March 26, 2026.
Meta's stock fell over 7% on March 26, 2026, after two separate jury rulings found the company liable for failing to protect underage users, with total damages awarded of over $380 million.
A class action lawsuit against NVIDIA is reported to be revived on March 26, 2026, regarding cryptocurrency mining disclosures; legal uncertainties are expected to cause a price impact of at least 5%.
On March 26, 2026, CATL participated in a fair competition symposium held by China's State Administration for Market Regulation (SAMR) to discuss regulating intense domestic competition and supporting overseas expansion.
Microsoft announced the completion of its latest Information Security Registered Assessors Program (IRAP) assessments in Australia for Azure, Dynamics 365, and Microsoft 365, supporting workloads up to the 'Protected' level.
On March 26, 2026, Netflix announced it was increasing prices across all its US subscription plans, resulting in a 1.13% stock price increase.
Bernstein downgraded Qualcomm stock to 'Market Perform' and lowered its price target to $140 on March 26, 2026; low importance is justified by the typical 1-3% price impact from analyst rating changes, forecasted.
Reported Q4 and full-year 2025 results on March 25, 2026. Full-year 2025 adjusted net profit rose 16.5% to RMB 20.6 billion and the company proposed a final dividend of HK$0.69 per share.
Announced strong full-year 2025 financial results on March 25, 2026. Revenue grew 13.02% YoY to RMB 31.63 billion, and net profit attributable to shareholders increased 21.69% YoY to RMB 7.71 billion, driven by a 26.09% increase in innovative drug sales.
Announcement of full-year 2025 financial results on March 25, 2026, reporting a 201.2% YoY revenue increase to RMB 802.6 million and achieving its first annual net profit turnaround, scheduled; High importance estimated as major turnarounds and triple-digit growth typically result in >10% price impact.
Announced full-year 2025 financial results, reporting the first-ever quarterly net profit of RMB 104 million in Q4 2025, which significantly exceeded market expectations. The positive result was driven by strong growth in the robotics LiDAR segment.
According to China Passenger Car Association data released around March 25, 2026, CATL's domestic power battery market share for Q1 2026 returned to 50.1%, regaining a majority share for the first time in five years.
InnoCare Pharma announced its FY2025 results on March 25, 2026, reporting its first-ever annual profit of RMB 644 million and revenue growth of 135.3% year-over-year.
Released FY2025 results on March 25, 2026, with revenue down 6% to RMB 9.68B and net profit up 29% to RMB 2.00B; shares rose over 9% on March 26, 2026.
On March 25, 2026, Akeso announced it received NMPA clearance to initiate Phase II clinical trials for two ADCs, AK146D1 and AK138D1, advancing its 'IO 2.0 + ADC 2.0' strategy. Medium importance estimated due to potential for >5% price impact from clinical progress, scheduled.
Granted 19.13 million award shares to employees under the share award scheme on March 25, 2026. This routine corporate action is estimated to have a minimal market impact of approximately 1%.
Salesforce announced on March 25, 2026, that it will freeze base salaries for employees at the director level and above in 2026 while increasing stock and bonus pools for top performers.
Micron announced cash tender offers to purchase any and all of certain outstanding series of its senior notes.
Reported full-year 2025 results on March 24, 2026, with revenue up 32.9% YoY to CNY 5.015 billion and net loss narrowing by 58.6% to CNY 1.766 billion. Achieved first-ever positive adjusted EBITDA and operating cash flow in H2 2025.
Announced audited annual results for the year ended December 31, 2025. Revenue increased by 16.7% year-over-year to RMB 21.8 billion, and adjusted net profit rose by 22.0% year-over-year to RMB 6.6 billion.
New York City Health + Hospital Corporation (NYCHHC) announced on March 24, 2026, that it will not renew its contract with Palantir upon its expiration in October 2026, following public pressure from activist groups.
Announced that the Phase 3 STAR study of its eye disease drug Efdamrofusp Alfa (IBI302) met its primary endpoint, demonstrating non-inferiority to Eylea for treating neovascular age-related macular degeneration (nAMD). The drug also showed potential for less frequent dosing. [Estimate: Medium importance due to significant Phase 3 clinical milestone].
Announced a five-year, $970 million blanket purchase agreement with the U.S. Defense Information Systems Agency (DISA) on March 24, 2026, to provide VMware Cloud Foundation and other software solutions. Medium importance is estimated as this contract represents a significant multi-year revenue stream, expected.
Thermo Fisher Scientific completed the acquisition of Clario Holdings, Inc. on 2026-03-24, scheduled. This acquisition is expected to contribute $0.45 to adjusted EPS, likely resulting in a 5-10% price impact.
Announced on 2026-03-24 that the IND application for SKB103 was approved by the NMPA for advanced solid tumors; Low importance estimated as an early-stage clinical milestone expected.
Announced full-year 2025 results on March 23, 2026, with revenue increasing 46.7% YoY to RMB 5.944 billion and adjusted net profit rising 69.9% YoY to RMB 1.559 billion.
Announced full-year 2025 results on March 23, 2026, with revenue increasing 15.8% YoY to RMB 45.46 billion and net profit attributable to shareholders rising 102.65% to RMB 19.15 billion, partly due to a one-time gain from a stake sale.
Announced fiscal year 2025 results on 2026-03-23, reporting revenue of RMB 2.06 billion (+6.5%) and a net loss of RMB 382 million (+43.2%); High importance estimated due to significant loss widening expected.
On March 23, 2026, the company entered into an asset purchase agreement with Corxel Pharmaceuticals to acquire the rights to develop, manufacture, and commercialize CARDAMYST™ (etripamil) nasal spray in Greater China for an upfront payment of US$30 million. Medium importance as it expands the product pipeline with a significant investment, scheduled.
Provided 2026 full-year guidance on March 23, 2026, where the company forecasts revenue between RMB 51.3 billion and RMB 53.0 billion, representing 18% to 22% growth for continuing operations, forecasted.
Announced that its antibody-drug conjugate (ADC) Disitamab Vedotin was approved by China's NMPA for its 4th indication: treatment of HER2-low expressing breast cancer with liver metastases; Medium importance reflects the positive regulatory milestone likely to cause >5% price impact.
The UK's Financial Conduct Authority (FCA) confirmed on March 23, 2026, that it awarded Palantir a three-month contract to analyze sensitive internal data to help combat financial crime.
Announced that the first participant has been dosed in a Phase 3 clinical study of IBI128 (Tigulixostat), a treatment for gout, in China. [Estimate: Low importance as initial dosing in a Phase 3 trial is a routine update].
Quarterly dividend of $0.65 per share, with the ex-dividend date on March 23, 2026. The dividend is payable on March 31, 2026. Low importance is estimated as this is a routine quarterly dividend payment, expected.